FibroBiologics (FBLG) Cash from Investing Activities (2023 - 2025)
FibroBiologics (FBLG) posted quarterly Cash from Investing Activities of -$6000.0 for Q3 2025, up 45.45% year-over-year from -$4125.0 in Q3 2024, and up 97.18% on a QoQ basis from -$213000.0 in Q2 2025.
FibroBiologics (FBLG) Cash from Investing Activities (2023 - 2025) Analysis & Trends
FibroBiologics has reported Cash from Investing Activities for 3 years, with the latest figure at -$6000.0 in Q3 2025.
- Cash from Investing Activities for Q3 2025 came in at -$6000.0, up 45.45% year-over-year; the trailing twelve-month figure through Jun 2026 was -$6000.0 (up 98.36% YoY), and the FY2025 annual result was -$262000.0, down 42.39% from the prior year.
- Cash from Investing Activities advanced to -$6000.0 in Q3 2025, from -$213000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$2000.0 in Q4 2023 and troughed at -$413000.0 in Q3 2023.
- A 3-year average of -$85545.5 and a median of -$43000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The largest YoY upside for Cash from Investing Activities was 97.34% in 2024 against a maximum downside of 4850.0% in 2024.
- A 3-year view of Cash from Investing Activities shows it stood at -$2000.0 in 2023, then slumped by 4850.0% to -$99000.0 in 2024, then soared by 93.94% to -$6000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$6000.0 in Q3 2025, -$213000.0 in Q2 2025, and -$43000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -213,000.00 |
| Jun 30, 2025 | -213,000.00 |
| Mar 31, 2025 | -43,000.00 |
| Mar 31, 2025 | -43,000.00 |
| Dec 31, 2024 | -99,000.00 |
| Dec 31, 2024 | -99,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -66,000.00 |
| Jun 30, 2024 | -66,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | -413,000.00 |
| Sep 30, 2023 | -413,000.00 |
| Jun 30, 2023 | -24,000.00 |
| Jun 30, 2023 | -24,000.00 |